Cargando…

Efficacy and Safety of a New Sustained-release Pregabalin Formulation Compared With Immediate-release Pregabalin in Patients With Peripheral Neuropathic Pain: A Randomized Noninferiority Phase 3 Trial

This study investigated whether a new sustained-release (SR) pregabalin formulation is noninferior to immediate-release (IR) pregabalin in alleviating peripheral neuropathic pain in Korean patients. MATERIALS AND METHODS: This was a randomized, double-blind, active-controlled phase 3 study of patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Kyung Ah, Lee, Yong-Ho, Son, Hyun-Shik, Song, Ki-Ho, Kim, Sang Yong, Chung, Choon Hee, Jang, Hak Chul, Lee, Kwan-Woo, Cha, Bong Yun, Song, Kee-Ho, Ko, Young Kwon, Lee, Pyung-Bok, Kim, Beom Joon, Kim, Sohee, An, Taewon, Kim, Yong-Chul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8994039/
https://www.ncbi.nlm.nih.gov/pubmed/35220330
http://dx.doi.org/10.1097/AJP.0000000000001028
_version_ 1784684025175080960
author Han, Kyung Ah
Lee, Yong-Ho
Son, Hyun-Shik
Song, Ki-Ho
Kim, Sang Yong
Chung, Choon Hee
Jang, Hak Chul
Lee, Kwan-Woo
Cha, Bong Yun
Song, Kee-Ho
Ko, Young Kwon
Lee, Pyung-Bok
Kim, Beom Joon
Kim, Sohee
An, Taewon
Kim, Yong-Chul
author_facet Han, Kyung Ah
Lee, Yong-Ho
Son, Hyun-Shik
Song, Ki-Ho
Kim, Sang Yong
Chung, Choon Hee
Jang, Hak Chul
Lee, Kwan-Woo
Cha, Bong Yun
Song, Kee-Ho
Ko, Young Kwon
Lee, Pyung-Bok
Kim, Beom Joon
Kim, Sohee
An, Taewon
Kim, Yong-Chul
author_sort Han, Kyung Ah
collection PubMed
description This study investigated whether a new sustained-release (SR) pregabalin formulation is noninferior to immediate-release (IR) pregabalin in alleviating peripheral neuropathic pain in Korean patients. MATERIALS AND METHODS: This was a randomized, double-blind, active-controlled phase 3 study of patients with diabetic peripheral neuropathy or postherpetic neuralgia from 41 sites in South Korea in 2017-2018. Eligible patients were randomized (1:1) to receive once-daily SR pregabalin or twice-daily IR pregabalin (150 to 600 mg/d) in a double-dummy manner for 12 weeks according to a stratified permuted block randomization scheme. The primary endpoint was the Daily Pain Rating Scale score at the end of treatment, averaged from the last 7 available scores. RESULTS: A total of 319 of 371 (86.0%) randomized patients completed the 12-week treatment (SR pregabalin: n=154; IR pregabalin: n=165; per-protocol set: n=296). The least square mean difference between both groups for the primary endpoint was 0.06 (SE 0.19); (95% confidence interval −0.31 to 0.42), with the lower limit of the confidence interval above the pre-specified margin (−0.78; P (noninferiority)<0.0001). Drug-related treatment-emergent adverse events (TEAEs) were comparable between both groups. The incidence of drug-related TEAEs leading to treatment discontinuation was low (SR pregabalin: 2.7%; IR pregabalin: 1.1%). No serious drug-related TEAEs or deaths occurred. DISCUSSION: The results demonstrate that the new once-daily SR pregabalin formulation is noninferior to twice-daily IR pregabalin in reducing peripheral neuropathic pain and is well tolerated in Korean patients with diabetic peripheral neuropathy or postherpetic neuralgia after 12 weeks of treatment.
format Online
Article
Text
id pubmed-8994039
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-89940392022-04-13 Efficacy and Safety of a New Sustained-release Pregabalin Formulation Compared With Immediate-release Pregabalin in Patients With Peripheral Neuropathic Pain: A Randomized Noninferiority Phase 3 Trial Han, Kyung Ah Lee, Yong-Ho Son, Hyun-Shik Song, Ki-Ho Kim, Sang Yong Chung, Choon Hee Jang, Hak Chul Lee, Kwan-Woo Cha, Bong Yun Song, Kee-Ho Ko, Young Kwon Lee, Pyung-Bok Kim, Beom Joon Kim, Sohee An, Taewon Kim, Yong-Chul Clin J Pain Original Articles This study investigated whether a new sustained-release (SR) pregabalin formulation is noninferior to immediate-release (IR) pregabalin in alleviating peripheral neuropathic pain in Korean patients. MATERIALS AND METHODS: This was a randomized, double-blind, active-controlled phase 3 study of patients with diabetic peripheral neuropathy or postherpetic neuralgia from 41 sites in South Korea in 2017-2018. Eligible patients were randomized (1:1) to receive once-daily SR pregabalin or twice-daily IR pregabalin (150 to 600 mg/d) in a double-dummy manner for 12 weeks according to a stratified permuted block randomization scheme. The primary endpoint was the Daily Pain Rating Scale score at the end of treatment, averaged from the last 7 available scores. RESULTS: A total of 319 of 371 (86.0%) randomized patients completed the 12-week treatment (SR pregabalin: n=154; IR pregabalin: n=165; per-protocol set: n=296). The least square mean difference between both groups for the primary endpoint was 0.06 (SE 0.19); (95% confidence interval −0.31 to 0.42), with the lower limit of the confidence interval above the pre-specified margin (−0.78; P (noninferiority)<0.0001). Drug-related treatment-emergent adverse events (TEAEs) were comparable between both groups. The incidence of drug-related TEAEs leading to treatment discontinuation was low (SR pregabalin: 2.7%; IR pregabalin: 1.1%). No serious drug-related TEAEs or deaths occurred. DISCUSSION: The results demonstrate that the new once-daily SR pregabalin formulation is noninferior to twice-daily IR pregabalin in reducing peripheral neuropathic pain and is well tolerated in Korean patients with diabetic peripheral neuropathy or postherpetic neuralgia after 12 weeks of treatment. Lippincott Williams & Wilkins 2022-02-28 /pmc/articles/PMC8994039/ /pubmed/35220330 http://dx.doi.org/10.1097/AJP.0000000000001028 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/)
spellingShingle Original Articles
Han, Kyung Ah
Lee, Yong-Ho
Son, Hyun-Shik
Song, Ki-Ho
Kim, Sang Yong
Chung, Choon Hee
Jang, Hak Chul
Lee, Kwan-Woo
Cha, Bong Yun
Song, Kee-Ho
Ko, Young Kwon
Lee, Pyung-Bok
Kim, Beom Joon
Kim, Sohee
An, Taewon
Kim, Yong-Chul
Efficacy and Safety of a New Sustained-release Pregabalin Formulation Compared With Immediate-release Pregabalin in Patients With Peripheral Neuropathic Pain: A Randomized Noninferiority Phase 3 Trial
title Efficacy and Safety of a New Sustained-release Pregabalin Formulation Compared With Immediate-release Pregabalin in Patients With Peripheral Neuropathic Pain: A Randomized Noninferiority Phase 3 Trial
title_full Efficacy and Safety of a New Sustained-release Pregabalin Formulation Compared With Immediate-release Pregabalin in Patients With Peripheral Neuropathic Pain: A Randomized Noninferiority Phase 3 Trial
title_fullStr Efficacy and Safety of a New Sustained-release Pregabalin Formulation Compared With Immediate-release Pregabalin in Patients With Peripheral Neuropathic Pain: A Randomized Noninferiority Phase 3 Trial
title_full_unstemmed Efficacy and Safety of a New Sustained-release Pregabalin Formulation Compared With Immediate-release Pregabalin in Patients With Peripheral Neuropathic Pain: A Randomized Noninferiority Phase 3 Trial
title_short Efficacy and Safety of a New Sustained-release Pregabalin Formulation Compared With Immediate-release Pregabalin in Patients With Peripheral Neuropathic Pain: A Randomized Noninferiority Phase 3 Trial
title_sort efficacy and safety of a new sustained-release pregabalin formulation compared with immediate-release pregabalin in patients with peripheral neuropathic pain: a randomized noninferiority phase 3 trial
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8994039/
https://www.ncbi.nlm.nih.gov/pubmed/35220330
http://dx.doi.org/10.1097/AJP.0000000000001028
work_keys_str_mv AT hankyungah efficacyandsafetyofanewsustainedreleasepregabalinformulationcomparedwithimmediatereleasepregabalininpatientswithperipheralneuropathicpainarandomizednoninferiorityphase3trial
AT leeyongho efficacyandsafetyofanewsustainedreleasepregabalinformulationcomparedwithimmediatereleasepregabalininpatientswithperipheralneuropathicpainarandomizednoninferiorityphase3trial
AT sonhyunshik efficacyandsafetyofanewsustainedreleasepregabalinformulationcomparedwithimmediatereleasepregabalininpatientswithperipheralneuropathicpainarandomizednoninferiorityphase3trial
AT songkiho efficacyandsafetyofanewsustainedreleasepregabalinformulationcomparedwithimmediatereleasepregabalininpatientswithperipheralneuropathicpainarandomizednoninferiorityphase3trial
AT kimsangyong efficacyandsafetyofanewsustainedreleasepregabalinformulationcomparedwithimmediatereleasepregabalininpatientswithperipheralneuropathicpainarandomizednoninferiorityphase3trial
AT chungchoonhee efficacyandsafetyofanewsustainedreleasepregabalinformulationcomparedwithimmediatereleasepregabalininpatientswithperipheralneuropathicpainarandomizednoninferiorityphase3trial
AT janghakchul efficacyandsafetyofanewsustainedreleasepregabalinformulationcomparedwithimmediatereleasepregabalininpatientswithperipheralneuropathicpainarandomizednoninferiorityphase3trial
AT leekwanwoo efficacyandsafetyofanewsustainedreleasepregabalinformulationcomparedwithimmediatereleasepregabalininpatientswithperipheralneuropathicpainarandomizednoninferiorityphase3trial
AT chabongyun efficacyandsafetyofanewsustainedreleasepregabalinformulationcomparedwithimmediatereleasepregabalininpatientswithperipheralneuropathicpainarandomizednoninferiorityphase3trial
AT songkeeho efficacyandsafetyofanewsustainedreleasepregabalinformulationcomparedwithimmediatereleasepregabalininpatientswithperipheralneuropathicpainarandomizednoninferiorityphase3trial
AT koyoungkwon efficacyandsafetyofanewsustainedreleasepregabalinformulationcomparedwithimmediatereleasepregabalininpatientswithperipheralneuropathicpainarandomizednoninferiorityphase3trial
AT leepyungbok efficacyandsafetyofanewsustainedreleasepregabalinformulationcomparedwithimmediatereleasepregabalininpatientswithperipheralneuropathicpainarandomizednoninferiorityphase3trial
AT kimbeomjoon efficacyandsafetyofanewsustainedreleasepregabalinformulationcomparedwithimmediatereleasepregabalininpatientswithperipheralneuropathicpainarandomizednoninferiorityphase3trial
AT kimsohee efficacyandsafetyofanewsustainedreleasepregabalinformulationcomparedwithimmediatereleasepregabalininpatientswithperipheralneuropathicpainarandomizednoninferiorityphase3trial
AT antaewon efficacyandsafetyofanewsustainedreleasepregabalinformulationcomparedwithimmediatereleasepregabalininpatientswithperipheralneuropathicpainarandomizednoninferiorityphase3trial
AT kimyongchul efficacyandsafetyofanewsustainedreleasepregabalinformulationcomparedwithimmediatereleasepregabalininpatientswithperipheralneuropathicpainarandomizednoninferiorityphase3trial